Navigation Links
Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
Date:10/29/2009

435 Costs and expenses: Cost of revenues 275,385 (54,860) (1) 220,525 Selling, general and administrative 389,520 (2,549) (2) 386,971 Research and development 136,612 (61,120) (3) 75,492 Acquisition-related items 41,222 (41,222) (4) Operating income 226,696 159,751 386,447 Interest expense, net 28,213 (10,699) (5) 17,514 Other (income) expense, net (5,629) 6,030 (6) 401 Income before income taxes 204,112 164,420 368,532 Income taxes 85,624 43,767 (7) 129,391 Net income $118,488 $120,653 $239,141 Diluted earnings per share $1.01 -- $2.04 Diluted weighted average shares 117,401 -- 117,401

Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:

  1. To exclude amortization of commercial intangible assets related to marketed products of $43,714 and the impact of an Indevus inventory step-up recorded as part of acquisition accounting of $11,146.
  2. To exclude certain separation payments.
  3. To exclude upfront and milestone payments to partners.
  4. To exclude Indevus transaction and separation costs of $37,982 as well as the impact, under purchase accounting, of a loss recorded to reflect the change in the company's current estimate of fair value, in accordance with GAAP, of the contingent consideration associated with the Indevus acquisition of $3,240.
  5. To exclude additional interest expense as a result of adopting FSP APB 14-1 of $11,667 and to exclude the amortization of the premium on debt acquired from Indevus of ($968).
  6. To exclude changes in fair value of financial
    '/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
2. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
4. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
5. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
6. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
7. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
8. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
9. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
10. BioMarin Acquires Huxley Pharmaceuticals, Inc.
11. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... CLEVELAND , Jan. 22, 2015  ViewRay™, a privately ... entered into an exclusive distributor agreement with ITOCHU Corporation ... radiation therapy system for the treatment of cancer in ... (me-rid-i-an) system, is the world,s first and only MRI-guided ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... diagnostic procedures in cardiology. The idea of publishing an ... of European cardiovascular imagers, is therefore long awaited. The ... with a patient rather than technology-based approach, helping clinicians ... aid of imaging. The book is divided ...
... ... of Fortune 1000 employers strongly indicates that wellness programs have a positive impact on ... ... of Fortune 1000 companies reveals that 78 percent of employers have improved employee participation ...
... , SCHAFFHAUSEN, Switzerland, Dec. 16 Tyco International Ltd. ... Michael E. Daniels for election to the Tyco Board of ... 2010. , Daniels, 55, is Senior Vice President of ... In this role, he has worldwide responsibility for IBM,s Global ...
... , BOCA RATON, Fla., Dec. 16 Dale Buchanan, owner ... have a weight loss contest for his students in the new year. The ... own prize or against each other. They will be losing weight to raise ... , "For every pound each student of mine loses between January 4 ...
... to 11-month interval lessens complication risks , TUESDAY, Dec. 15 (HealthDay ... such a profound impact on your life that you just can,t ... suggests that you might want to wait at least six months ... be even better. , The study found that when the ...
... ... received a further 1.6 million Euro in capital funding to scale up production and ... for this promising new technology. The capital was invested by LD Pensions and Unisense A/S ... ...
Cached Medicine News:Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3Health News:Hallmark Insights' Employer Survey Reveals Cost-Savings Benefits of Health & Wellness Programs 2Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: